Biochemical mechanisms of action of antidepressants

1. Simon GE, et al. Is the lifetime risk of depression actually increasing? J Clin Epidemiol 1995; 48(9): 1109–1118.

2. Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative. World Psychiatry 2007; 6: 168–176.

3. Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990–2020. In: Murray CJL, et al. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Mass: Harvard School of Public Health on behalf of the WHO and the World Bank 1996; 325–395.

4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498–1504.

5. Mathers CD, Lopez AD, Murray ChJL. The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001. In: Lopez AD, et al. Global Burden of Disease and Risk Factors. Disease Control Priorities Project. Washington (DC): World Bank 2006; 45–93.

6. WHO. Depression. World Health Organization (WHO), Geneva 2011, http://www.who.int/mental_health/management/depre ssion/definition/en/

7. McEwen BS, et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010; 15(3): 237–249.

8. Fishback JA, et al. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 2010; 127(3): 271–282.

9. Popoli M. Agomelatine: innovative pharmacological approach in depression. CNS Drugs 2009; 23(Suppl 2): 27–34.

10. Švestka J, et al. Agomelatin – antidepresivum s novým mechanizmem působení. Psychiatrie 2010; 14(2): 98–108.

11. Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine_2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306(3): 954–964.

12. Bourin M, et al. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004; 29(2): 126–133.

13. Anttila SA, et al. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7(3): 249–264.

14. Hamik A, et al. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990; 28(2): 99–109.

15. Bartoszyk GD, et al. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT_1A receptor agonistic properties. Eur J Pharmacol 1997; 322(2–3): 147–153.

16. Tatsumi M, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340(2–3): 249–258.

17. Fisar Z, et al. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010; 31(5): 645–656.

18. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76(5): 511–527.

19. Fišar Z, et al. Serotonergní účinky antidepresiv. Česká a slovenská psychiatrie 2011; 107: (2): 115–120.

20. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003; 64(Suppl 13): 5–12.

21. Nikolaus S, et al. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res 2009; 204(1): 32–66.

22. Duman RS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 2009; 11(3): 239–255.

23. Maes M, et al. The inflammatory & neurodegenerative (I & ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24(1): 27–53.

24. Nikisch G. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function. Neuro Endocrinol Lett 2009; 30(1): 11–16.

25. Bunney JN, et al. Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 2008; 86: 23–32.

26. Schulz P, et al. Neurobiology of circadian systems. CNS Drugs 2009; 23(Suppl 2): 3–13.

27. Mendlewicz J. Disruption of the circadian timing systems: molecular mechanisms in mood disorders. CNS Drugs 2009; 23(Suppl 2): 15–26.

28. Savitz J, et al. 5-HT_1A receptor function in major depressive disorder. Prog Neurobiol 2009; 88(1): 17–31.

29. Blier P, et al. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15(7): 220–226.

30. Blier P, et al. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998; 44(5): 313–323.

31. Blier P, et al. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53(3): 193–203.

32. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32(2): 86–102.

33. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14(10): 536–546.

34. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003; 13(2): 57–66.

35. Smith DF, et al. Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 2009; 19(9): 611–628.

36. Sargent PA, et al. Brain serotonin_1A receptor binding measured by positron emission tomography with [¹¹C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57(2): 174–180.

37. Bhagwagar Z, et al. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [¹¹C]WAY-100635. Mol Psychiatry 2004; 9(4): 386–392.

38. Drevets WC, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007; 34(7): 865–877.

39. Sargent PA, et al. 5-HT_1A receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-¹¹C]WAY-100635. J Affect Disord 2010; 123(1-3): 77–80.

40. Parsey RV, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006; 59(2): 106–113.

41. Moses-Kolko EL, et al. Measurement of 5-HT_1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [¹¹C]WAY-100635. Synapse 2007; 61(7): 523–530.

42. Praschak-Rieder N, et al. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [¹⁸F] MPPF positron emission tomography study. Biol Psychiatry 2004; 56(8): 587–591.

43. Meyer JH, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 2009; 66(12): 1304–1312.

44. Selvaraj S, et al. Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl) 2011; 213(2–3): 555–562.

45. Meyer JH, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63(11): 1209–1216.

46. Praschak-Rieder N, et al. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 2008; 65(9): 1072–1078.

47. Yang S, et al. Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2. Anesth Analg 2007; 104(5): 1179–1184.

48. Fišar Z, et al. Intracellular signalling pathways and mood disorders. Folia Biol (Praha) 2010; 56(4): 135–148.

49. Heiberg IL, et al. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002; 134(1–2): 479–484.

50. Paul IA, et al. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003; 1003: 250–272.

51. Gould TD, et al. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets 2007; 6(3): 193–204.

52. Chen G, et al. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry 2006; 19(3): 313–323.

53. Rapoport SI, et al. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 2009; 61(2): 185–209.

54. Machado-Vieira R, et al. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009; 123(2): 143–150.

55. Madaan V, et al. Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News Perspect 2009; 22(6): 319–324.

56. Flores BH, et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006; 31(3): 628–636.

57. Kehne JH. The CRF₁ receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders. CNS Neurol Disord Drug Targets 2007; 6(3): 163–182.

58. Linde K. St. John’s wort – an overview. Forsch Komplementmed 2009; 16(3): 146–155.

59. Ernst E, et al. Adverse effects profile of the herbal antidepressant St. John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54(8): 589–594.

60. Akhondzadeh Basti A, et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(2): 439–442.

61. Akhondzadeh S, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology (Berl) 2010; 207(4): 637–643.

62. Kulkarni SK, et al. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010; 24(3): 317–324.

63. Seol GH, et al. Antidepressant-like effect of Salvia sclarea is explained by modulation of dopamine activities in rats. J Ethnopharmacol 2010; 130(1): 187–190.

64. Setzer WN. Essential oils and anxiolytic aromatherapy. Nat Prod Commun 2009; 4(9): 1305–1316.

65. Delgado PL, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999; 46(2): 212–220.

66. Sontrop J, et al. ω-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 2006; 42(1): 4–13.

67. Nemets H, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163(6): 1098–1100.

68. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009; 70(Suppl 5): 7–11.

69. Appleton KM, et al. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91(3): 757–770.

70. Hibbeln JR, et al. Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: implications for the biophysical role of highly unsaturated fatty acids. Am J Clin Nutr 2000; 71(1 Suppl): 331S–338S.

71. Horrobin DF, et al. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999; 60(4): 217–234.

72. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97(6): 1634–1658.

73. Cumurcu BE, et al. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 2009; 63(5): 639–645.

74. Gałecki P, et al. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009; 61(3): 436–447.

75. BolaĖos JP, et al. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications. Adv Drug Deliv Rev 2009; 61(14): 1299–1315.

76. Valko M, et al. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12(10): 1161–1208.

77. Gutteridge JM, et al. Antioxidants: Molecules, medicines, and myths. Biochem Biophys Res Commun 2010; 393(4): 561–564.

78. Raboch J. Kognitivní funkce, stárnutí a stravovací návyky. Čes a slov psychiat 2010; 106(2): 81–86.

79. Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev 2008; 13(3): 216–226.

80. Tanti A, et al. Open questions in current models of antidepressant action. Br J Pharmacol 2010; 159(6): 1187–1200.

81. Diazgranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67(8): 793–802.

82. Kennaway DJ. Clock genes at the heart of depression. J Psychopharmacol 2010; 24(8): 5–14.

83. Halene TB, et al. PDE inhibitors in psychiatry – future options for dementia, depression and schizophrenia? Drug Discov Today 2007; 12(19-20): 870–878.

84. Cashman JR, et al. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. J Med Chem 2009; 52(6): 1530–1539.

85. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr 2009; 14(2): 71–73.

86. Fišar Z, et al. Depression, antidepressants, and peripheral blood components. Neuro Endocrinol Lett 2008; 29(1): 17–28.